Sylvie Laquerre

5.4k total citations
44 papers, 2.5k citations indexed

About

Sylvie Laquerre is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Sylvie Laquerre has authored 44 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 20 papers in Oncology and 9 papers in Epidemiology. Recurrent topics in Sylvie Laquerre's work include Virus-based gene therapy research (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Herpesvirus Infections and Treatments (8 papers). Sylvie Laquerre is often cited by papers focused on Virus-based gene therapy research (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Herpesvirus Infections and Treatments (8 papers). Sylvie Laquerre collaborates with scholars based in United States, Canada and United Kingdom. Sylvie Laquerre's co-authors include Maureen R. Bleam, Joseph C. Glorioso, Dina Anderson, Katherine G. Moss, Aidan G. Gilmartin, Kimberly N. Smitheman, Jingsong Yang, Rafaela Argnani, David Sutton and Symon G. Erskine and has published in prestigious journals such as PLoS ONE, Biochemistry and Cancer Research.

In The Last Decade

Sylvie Laquerre

41 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sylvie Laquerre United States	22	1.6k	1.0k	416	383	316	44	2.5k
Neil P. Shah United States	38	2.4k 1.6×	1.2k 1.2×	209 0.5×	343 0.9×	232 0.7×	181	7.7k
Kui Shen United States	20	1.5k 0.9×	947 0.9×	146 0.4×	426 1.1×	107 0.3×	44	2.5k
Margaret P. Quinlan United States	15	2.0k 1.3×	1.1k 1.0×	465 1.1×	435 1.1×	467 1.5×	29	3.1k
Matthew J. Davis United States	9	1.0k 0.6×	637 0.6×	180 0.4×	204 0.5×	90 0.3×	14	1.6k
Philip Friedlander United States	22	2.2k 1.4×	2.1k 2.0×	735 1.8×	272 0.7×	518 1.6×	61	3.8k
Wilhelm G. Dirks Germany	28	1.8k 1.2×	796 0.8×	218 0.5×	234 0.6×	380 1.2×	76	3.1k
Nuri A. Temiz United States	21	1.9k 1.2×	588 0.6×	406 1.0×	232 0.6×	318 1.0×	43	2.7k
Isabelle Rooney United States	25	1.0k 0.6×	618 0.6×	354 0.9×	374 1.0×	149 0.5×	49	2.5k
Michael J. Mitten United States	16	1.9k 1.2×	832 0.8×	270 0.6×	197 0.5×	34 0.1×	27	2.8k
Giordano Caponigro United States	22	2.0k 1.3×	674 0.7×	93 0.2×	392 1.0×	136 0.4×	46	2.7k

Countries citing papers authored by Sylvie Laquerre

Since Specialization

Citations

This map shows the geographic impact of Sylvie Laquerre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Laquerre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Laquerre more than expected).

Fields of papers citing papers by Sylvie Laquerre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvie Laquerre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Laquerre. The network helps show where Sylvie Laquerre may publish in the future.

Co-authorship network of co-authors of Sylvie Laquerre

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvie Laquerre. A scholar is included among the top collaborators of Sylvie Laquerre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvie Laquerre. Sylvie Laquerre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Henley, Benjamin J., Stacey L. Lehman, Himanshu Gupta, et al.. (2024). Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression. npj Precision Oncology. 8(1). 192–192. 6 indexed citations

Smans, Karine, Katrin Sproesser, Kathryn Packman, et al.. (2024). 144 (PB132): JNJ-79032421 is a novel membrane restricted mesothelin targeting Tcell engaging bispecific antibody for treatment of mesothelin-positive cancers. European Journal of Cancer. 211. 114666–114666.

Qin, Donghui, Xiaojuan Lin, Yan Chen, et al.. (2021). Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors. ACS Medicinal Chemistry Letters. 12(6). 1005–1010. 7 indexed citations

Vijayaraghavan, Smruthi, Lorraine Lipfert, Kristen Chevalier, et al.. (2020). Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Molecular Cancer Therapeutics. 19(10). 2044–2056. 138 indexed citations

Park, K., Myung‐Ju Ahn, Min Hee Hong, et al.. (2018). OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 13(10). S344–S345. 7 indexed citations

Emdal, Kristina B., et al.. (2017). Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance. Molecular Cancer Therapeutics. 16(11). 2572–2585. 23 indexed citations

Emdal, Kristina B., et al.. (2017). Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistance. PMC. 1 indexed citations

Moores, Sheri L., Mark L. Chiu, Barbara S. Bushey, et al.. (2016). A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors. Cancer Research. 76(13). 3942–3953. 188 indexed citations

King, Alastair J., Marc R. Arnone, Maureen R. Bleam, et al.. (2013). Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions. PLoS ONE. 8(7). e67583–e67583. 163 indexed citations

10.

Greger, James, Stephen D. Eastman, Vivian Zhang, et al.. (2012). Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations. Molecular Cancer Therapeutics. 11(4). 909–920. 260 indexed citations

11.

Gilmartin, Aidan G., Maureen R. Bleam, Arthur Groy, et al.. (2011). GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition. Clinical Cancer Research. 17(5). 989–1000. 459 indexed citations

12.

Jing, Junping, Joel Greshock, Joanna D. Holbrook, et al.. (2011). Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212. Molecular Cancer Therapeutics. 11(3). 720–729. 96 indexed citations

13.

Qian, Yongzhen, Emily Hua, Kheem S. Bisht, et al.. (2011). Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clinical & Experimental Metastasis. 28(8). 899–908. 33 indexed citations

14.

Degenhardt, Yan, Joel Greshock, Sylvie Laquerre, et al.. (2010). Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability. Molecular Cancer Therapeutics. 9(7). 2079–2089. 73 indexed citations

15.

Gilmartin, Aidan G., Maureen R. Bleam, Mark C. Richter, et al.. (2009). Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis. Cancer Research. 69(17). 6969–6977. 100 indexed citations

16.

Heiser, Laura M., Nicholas J. Wang, Carolyn Talcott, et al.. (2009). Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome biology. 10(3). R31–R31. 46 indexed citations

17.

Sutton, David, Melody Diamond, Leo F. Faucette, et al.. (2007). Efficacy of GSK461364, a selective Plk1 inhibitor, in human tumor xenograft models. 67. 5388–5388. 4 indexed citations

18.

Wyde, Philip R., Sylvie Laquerre, Srikrishna N. Chetty, et al.. (2005). Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Research. 68(1). 18–26. 26 indexed citations

19.

Bolken, Tové C., Sylvie Laquerre, Yi Zhang, et al.. (2005). Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Research. 69(2). 86–97. 83 indexed citations

20.

Laquerre, Sylvie, William F. Goins, Shusuke Moriuchi, et al.. (1999). 8 Gene-transfer Tool: Herpes Simplex Virus Vectors. Cold Spring Harbor Monograph Archive. 36. 173–208. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact